Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.

Warlick ED.

Curr Opin Oncol. 2010 Mar;22(2):150-4. doi: 10.1097/CCO.0b013e328335a543. Review.

PMID:
20010295
2.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

4.

The evolution of hematopoietic SCT in myelodysplastic syndrome.

Kindwall-Keller T, Isola LM.

Bone Marrow Transplant. 2009 Apr;43(8):597-609. doi: 10.1038/bmt.2009.28. Epub 2009 Mar 2. Review.

PMID:
19252532
5.

Transplant strategies for patients with myelodysplastic syndromes.

Deeg HJ.

Curr Opin Hematol. 2006 Mar;13(2):61-6. Review.

PMID:
16456370
6.

Patient selection for transplantation in the myelodysplastic syndromes.

Cutler C.

Hematol Oncol Clin North Am. 2010 Apr;24(2):469-76. doi: 10.1016/j.hoc.2010.02.006. Review.

PMID:
20359638
7.
8.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Barosi G, Bacigalupo A.

Curr Opin Hematol. 2006 Mar;13(2):74-8. Review.

PMID:
16456372
10.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.

Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.

Bone Marrow Transplant. 2001 Oct;28(7):643-7.

11.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
12.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.

Deeg HJ, Bartenstein M.

Arch Immunol Ther Exp (Warsz). 2012 Feb;60(1):31-41. doi: 10.1007/s00005-011-0152-z. Epub 2011 Dec 6. Review.

PMID:
22143157
13.

When to transplant MDS, and what to do when transplant fails.

Sockel K, Platzbecker U.

Curr Hematol Malig Rep. 2013 Dec;8(4):379-85. doi: 10.1007/s11899-013-0181-2. Review.

PMID:
24091832
14.

Hemopoietic cell transplantation for the myelodysplastic syndromes.

Scott BL, Deeg HJ.

Arch Immunol Ther Exp (Warsz). 2005 Jul-Aug;53(4):297-307. Review.

PMID:
16088314
15.

Transplant strategies for myelodysplastic syndrome.

McCarty J.

Best Pract Res Clin Haematol. 2004 Dec;17(4):559-72. Review.

PMID:
15494294
16.

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.

Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak ML, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman SJ, O'Donnell MR.

Bone Marrow Transplant. 2007 Nov;40(9):843-50. Epub 2007 Aug 27.

PMID:
17724447
17.

Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Resnick IB, Shapira MY, Slavin S.

Transpl Immunol. 2005 Aug;14(3-4):207-19. Epub 2005 Apr 26. Review.

PMID:
15982565
18.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.

Platzbecker U, Ehninger G, Schmitz N, Bornhäuser M.

Ann Hematol. 2003 Aug;82(8):463-8. Epub 2003 Jun 21. Review.

PMID:
12910373
19.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes.

Platzbecker U.

Semin Hematol. 2012 Oct;49(4):342-9. doi: 10.1053/j.seminhematol.2012.07.003. Review.

PMID:
23079064

Supplemental Content

Support Center